Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

17 April 2008 CSL Behring Submits NDS to Health Canada Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema

CSL Behring has filed a new drug submission (NDS) with Health Canada seeking approval to market its C1-esterase inhibitor concentrate in Canada for the treatment of hereditary angioedema (HAE), a rare and serious genetic disorder. The submission is based on the recently completed phase II/III prospective, double-blind placebo-controlled International Multi-center Prospective Angioedema C1-Inhibitor Trial (I.M.P.A.C.T.), the largest HAE trial ever conducted, that studied the efficacy of pasteurized C1-INH concentrate.

> Read More
01 April 2008 CSL Behring Signs Agreements with Canadian Blood Services and Héma-Québec to Supply Life-Saving Therapies

CSL Behring Canada, Inc. today announced that Canadian Blood Services, and Héma-Québec, have each awarded the company contracts to supply Helixate® FS ( Antihemophilic Factor [Recombinant]), Humate® P (Antihemophilic factor / von Willebrand Factor Complex [Human], Dried, Pasteurized), Privigen (Immune Globulin Intravenous [Human]), Vivaglobin® (Immune Globulin Subcutaneous [Human]) and other plasma-derived products. These products are used for the treatment of conditions such as hemophilia, von Willebrand Disease, primary immunodeficiency as well as other serious conditions.

> Read More
18 March 2008 C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study

C1-esterase inhibitor (C1-INH) concentrate is a safe and effective therapy that rapidly relieves acute abdominal and facial swelling attacks in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented today at the American Academy of Allergy, Asthma & Immunology (AAAAI) 64th Annual Meeting. Results from the prospective, double-blind International Multi-center Prospective Angioedema C1-Inhibitor Trial (I.M.P.A.C.T. 1), the largest HAE study ever conducted, showed patients receiving C1-INH concentrate had a median time to symptom relief of 30 minutes, versus 90 minutes for patients receiving placebo. Additionally, interim results from I.M.P.A.C.T. 2, also presented at AAAAI, demonstrated for the first time C1-INH replacement therapy’s effectiveness in rapidly relieving HAE attacks in peripheral body locations, such as the hands and feet.

> Read More
17 March 2008 Study Shows Privigen™10% Liquid Immunoglobulin Preparation for Intravenous Use, Is an Effective Replacement Therapy in Patients with Primary Immune Deficiencies

CSL Behring presented data today on the pharmacokinetic properties of its new immune globulin intravenous (human) 10% product, Privigen™. Researchers found that Privigen leads to immunoglobulin G (IgG) pharmacokinetic characteristics and specific antibody levels equivalent to those described for other intravenous immunoglobulin (IVIg) preparations. The study was presented at the American Academy of Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, U.S.

> Read More
17 March 2008 L-Proline Stabilized Immune Globulin Intravenous (Human) 10% Liquid, Privigen™, Demonstrates Good Tolerability at High Infusion Rates

CSL Behring announced data today from a study that demonstrates its new liquid immune globulin intravenous (human) 10% product (Privigen™), is well-tolerated in patients with Primary Immune Deficiencies (PI); a group of predominantly genetic disorders that cause a malfunction in part or all of the immune system. New data from an additional study also showed that Privigen is well-tolerated when administered at high infusion rates. Both studies were presented at the American Academy of Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, U.S.

> Read More
Page 48 of 52 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+